| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
NuCana plc$1.34
+0.16 (+12.9%)
D 32Pipeline Score Overvalued Biotech · Clinical
Market Cap
8.41 M
EPS
-33.32
P/E Ratio
-
Value Trade
30.16 K
-0.49 %
Week
-6.91 %
1 Month
-5.61 %
3 Month
-41.95 %
6 Month
-99.99 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
98.22 K
52 Week Range
1.33 - 40
% held by Insiders
6.99 %
% held by Institutions
1.36 %
Enterprise Value
-19.09 M
Total Shares
4.16 M
Short %
3.38 %
Float Shares
3.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NuCana plc
185Total events
2Upcoming
37Tier-1 (high impact)
2017 – 2029Coverage
Upcoming catalysts 2
Event history 183
Jan 1, 2026
2026
◆Topline ReadoutNUC-7738Clinical Data
Topline data from Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda in PD-1 inhibitor-resistant metastatic melanoma
PD-1 inhibitor-resistant metastatic melanomasource ↗
2026
◆Enrollment CompleteNUC-7738Trial
Complete patient recruitment in Phase 2 expansion study NuTide:701
PD-1 inhibitor-resistant metastatic melanomasource ↗
2026
◆Full ResultsNUC-7738Clinical Data
Announce final data from Phase 2 expansion study NuTide:701
PD-1 inhibitor-resistant metastatic melanomasource ↗
2026
◆FDA Feedback ReceivedNUC-7738FDA Meeting
Obtain regulatory guidance from FDA regarding registrational strategy for NUC-7738 in melanoma
melanomasource ↗
Dec 10, 2025
◆Poster PresentationNUC-7738Presentation
Poster presentation of Phase 2 expansion study of NUC-7738 in combination with pembrolizumab at ESMO IO 2025
PD-1 inhibitor-resistant cutaneous melanomasource ↗
Drug Pipeline Intelligence
D32
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 40%
Micro Cap (rank 548 of 911)
Percentile RankNuCana plc faces pipeline headwinds (32/100), with $162M risk-adjusted pipeline value, led by NUC-1031 in Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUC-1031 Small molecule | Cancer | Phase 1 | NCT01621854 | 10% | $98M | COMPLETED | 68 | - | - | Jun 1, 2015 | - | Mar 20, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NUC-7738 | PD-1 inhibitor-resistant melanoma | Phase 2 | 2026-03-19 | two partial responses; one of which was confirmed; multiple cases of stable disease; one patient whose disease converted to a complete metabolic response with no detectable active disease Read More | NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data fr Read More | |
NUC-7738 | PD-1 inhibitor-resistant melanoma | Phase 2 | 2026-03-19 | two partial responses; one of which was confirmed; multiple cases of stable disease; one patient whose disease converted to a complete metabolic response with no detectable active disease Read More | NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data fr Read More | |
NUC-7738 | PD-1 inhibitor-resistant melanoma | Phase 2 | 2026-03-19 | two partial responses; one of which was confirmed; multiple cases of stable disease; one patient whose disease converted to a complete metabolic response with no detectable active disease Read More | NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data fr Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NCNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NCNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NCNA▼ -6.9%on this news
NuCana Appoints Ian Webster as Chief Financial Officer
NuCana plc has appointed Ian Webster as Chief Financial Officer, effective immediately. Webster, who has been with the company since 2019, previously served as Interim CFO. His extensive experience in finance, particularly in the biopharmaceutical sector, positions him well to guide NuCana's financial strategy as the company advances its clinical pipeline, including the Phase 2 study of NUC-7738.
Read more →NCNA▲ +5.9%on this news· ran to +17% by day 1
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
NuCana plc reported its first quarter 2026 financial results, highlighting progress in its clinical development, particularly for NUC-7738, which has received FDA IND clearance. The company aims to advance its Phase 2 expansion study for NUC-7738 in melanoma and is exploring additional indications. Despite a net loss for the quarter, NuCana's cash resources are expected to support operations through 2029.
Read more →NCNA▲ +5.9%on this news· ran to +17% by day 1
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2026 2025 (in thousands, except per share data) Research and development expenses (3,213 ) (1,725 ) Administ
NuCana PLC released its unaudited consolidated financial results for the three months ended March 31, 2026. The report indicates a substantial increase in both operating losses and overall loss compared to the previous year, with operating loss rising to $4.42 million and total comprehensive loss increasing to $3.85 million. Research and development expenses have notably surged, rising from $1.73 million to $3.21 million. The company's losses reflect ongoing financial challenges as it continues to develop cancer treatments using its proprietary ProTide technology.
Read more →NCNAA New Era in Oncology Notice of 2026 Annual General Meeting Monday, 8th June 2026 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K. NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company
NuCana plc is set to hold its 2026 Annual General Meeting on June 8, 2026, at Lochside House, Edinburgh. The notice outlines various resolutions including the re-election of directors and the reappointment of auditors. The Company’s board emphasizes that passing these proposals is essential for maintaining its financial plans. Shareholders are encouraged to vote in advance by appointing the Chair as their proxy.
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data fr
NuCana plc (NASDAQ: NCNA) announced its fourth quarter and year-end 2025 financial results, highlighting the promising clinical activity of NUC-7738 in treating PD-1 inhibitor-resistant melanoma. The Phase 2 NuTide:701 study has shown efficacy, including partial responses and stable disease in patients. The company also reported a net loss of $2.5 million for Q4 2025, though it is optimistic about its cash resources extending into 2029. Future plans include completing enrollment in the expansion study and seeking regulatory guidance on possible approval pathways.
Read more →NCNANuCana Appoints Theresa Bruce as Chief Operating Officer Edinburgh, United Kingdom
NuCana plc has appointed Theresa Bruce as its new Chief Operating Officer, effective January 1, 2026. Bruce brings over 25 years of experience in oncology research and development, which NuCana anticipates will bolster its operational leadership. The company is focused on advancing its pipeline, particularly the Phase 1/2 study of NUC-7738, aimed at improving cancer treatment outcomes. NuCana expects to benefit from several data readouts in 2026, enhancing its market position in cancer therapies.
Read more →NCNANuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, an
NuCana plc presented promising clinical data for NUC-7738 at the ESMO Immuno-Oncology Congress 2025. The treatment demonstrated clinical activity in patients with PD-1 inhibitor-resistant metastatic melanoma, including confirmed partial responses and stable disease. No new safety signals were observed, reinforcing the treatment's favorable safety profile. The findings support ongoing patient enrollment in the trial, aimed at exploring the potential benefits of NUC-7738 further.
Read more →NCNA▼ -7.9%on this news
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2025 2024 2025 2024 (in thousands, except per share data) Resear
NuCana PLC reported its unaudited condensed consolidated financial performance for the three and nine months ending September 30, 2025, indicating a notable operating loss of $15.5 million. The results show a decrease in research and development expenditures, which is a positive sign. However, the company is still facing substantial cumulative losses and challenges related to cash flow management. They reported a modest increase in cash reserves, but ongoing financial uncertainty remains a key concern as they continue their biopharmaceutical developments.
Read more →NCNANuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China Edinburgh, United Kingdom
NuCana plc has received a composition-of-matter patent for NUC-7738 from the China National Intellectual Property Administration. This patent will bolster the company's worldwide patent strategy, aiding the ongoing Phase 1/2 clinical study involving NUC-7738 in patients with PD-1 inhibitor refractory melanoma. The CEO highlighted the encouraging clinical data supporting the drug's potential in cancer treatment. NuCana continues to advance its novel ProTide technology aimed at enhancing chemotherapy efficacy.
Read more →NCNANuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor- Infiltrating Lymphocytes at the ESMO Congress 2025 NUC-7738 Synergizes with P
NuCana announced promising data at the ESMO Congress 2025 regarding NUC-7738, particularly its synergy with PD-1 inhibitors in treating renal cell carcinoma. The data, derived from co-cultured patient-derived organoids, indicates that NUC-7738 could enhance the effectiveness of existing PD-1 therapies. The ongoing NuTide:701 study has shown a favorable safety profile and meaningful tumor reduction in melanoma patients unresponsive to PD-1 treatment. NuCana plans to expand patient recruitment and has received approval from regulators for this initiative.
Read more →NCNANuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off
NuCana plc announced promising data regarding their drug NUC-3373 in combination with pembrolizumab for patients with advanced solid tumors. The latest update reveals a patient with melanoma has remained progression-free for 23 months following treatment. Preclinical data further supports the drug's safety and efficacy, indicating potential advancements in treatment outcomes for cancer patients. The company is also exploring further clinical studies to optimize combination regimens.
Read more →NCNANuCana Compliant with All Nasdaq Continued Listing Criteria Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom
NuCana plc has confirmed compliance with all Nasdaq continued listing criteria, closing a previous listing matter. The company expects its cash resources to sustain operations and support key milestones through 2029. Additionally, NuCana's pipeline includes promising anti-cancer agents such as NUC-7738 and NUC-3373, with multiple upcoming data readouts that could enhance treatment outcomes for patients with cancer. The positive developments position NuCana favorably for future advancements in cancer therapy.
Read more →NCNANuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025 EDINBURGH, United Kingdom
NuCana plc announced that it will present data on NUC-7738's synergy with PD-1 inhibitors at the ESMO Congress 2025 in Berlin. The presentation, titled 'Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer,' is scheduled for October 19, 2025. NUC-7738 is being evaluated as a potential treatment for advanced solid tumors either as a monotherapy or in combination with pembrolizumab. NuCana's ProTide technology aims to enhance the efficacy of existing chemotherapy agents.
Read more →NCNA▼ -12.6%on this news
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2025 2024 2025 2024 (in thousands, except per share data) Research and deve
NuCana plc has released its unaudited condensed consolidated statements of operations for the six months ended June 30, 2025, depicting significant financial challenges. The company reported an operating loss of 24,442, larger than the previous year, driven by increased research and administrative expenses. A substantial net loss of 26,587 was recorded for the period, raising concerns about financial sustainability as the accumulated deficit reached 250,696. The report underscores ongoing hurdles as NuCana progresses in its development of innovative cancer therapies.
Read more →NCNA▼ -8.9%on this news
NuCana Announces ADS Ratio Change Edinburgh, United Kingdom
NuCana plc announced its decision to change the ratio of its American Depository Shares (ADSs) effective August 11, 2025. The new ratio will be one ADS representing five thousand ordinary shares, which effectively acts as a one-for-two hundred reverse split. This adjustment aims to bolster the liquidity of NuCana's ADSs and assist in aligning with Nasdaq's minimum bid price requirement. Registered holders must surrender their certificated ADSs, but those using the Direct Registration System will undergo an automatic exchange.
Read more →NCNA▲ +6.9%on this news
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution Edinburgh, United Kingdom
NuCana plc has successfully canceled all outstanding Series A Warrants after raising the necessary capital through its at-the-market offering. This cancellation, completed as of July 21, 2025, eliminates the overhanging rights from earlier offerings and represents a key strategic move for the company. NuCana is focused on enhancing treatment outcomes in cancer patients with its proprietary ProTide technology, and continues to advance its promising drug candidates NUC-7738 and NUC-3373 in clinical trials.
Read more →NCNA▼ -15.9%on this news
NuCana Announces Plan to Implement ADS Ratio Change Edinburgh, United Kingdom
NuCana plc announced a plan to change the ratio of its American Depository Shares (ADSs), effective August 8, 2025. The new ratio will be one ADS representing 5,000 ordinary shares, akin to a one-for-two hundred reverse ADS split. This move is designed to enhance liquidity and regain compliance with Nasdaq's minimum bid price requirement. While the change could positively influence the trading price of the ADSs, there are no guarantees regarding its effectiveness.
Read more →NCNA▼ -14.3%on this news· ran to +211% by day 3
Notice of 2025 Annual General Meeting Friday, 27th June 2025 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K. NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 2 NO
NuCana plc has announced its 2025 Annual General Meeting (AGM), which is set to take place on June 27, 2025, at Lochside House in Edinburgh, UK. The meeting will address several ordinary resolutions, including the re-election of directors Cyrille Leperlier and Elliott Levy, and the re-appointment of Ernst & Young LLP as auditors. The company's board recommends a favorable vote on all resolutions, highlighting their confidence in the proposals for the benefit of shareholders. Shareholders are encouraged to vote in advance, emphasizing the importance of participation.
Read more →NCNA▲ +7.6%on this news· ran to +69% by day 1shared move
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2025 2024 (in thousands, except per share data) Research and development expenses (1,725 ) (6,783 ) Administ
NuCana PLC reported its unaudited consolidated financial results for the three months ended March 31, 2025. The company experienced a reduction in losses compared to the same period in 2024, with a loss of $2.473 million versus $6.838 million the previous year. Total comprehensive loss for the quarter was $2.500 million, while operating losses were noted at $2.851 million, indicating ongoing financial challenges. The company's cash and cash equivalents decreased significantly over the year from $12.868 million to $3.953 million, raising concerns about liquidity.
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibito
NuCana has reported its fourth quarter and year-end 2024 financial results, indicating a promising outlook for its lead candidates NUC-7738 and NUC-3373. The company intends to initiate an expansion study for NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant melanoma. Positive preliminary data indicates NUC-7738's efficacy in reducing tumors, while NUC-3373 is under evaluation for advanced solid tumors and lung cancer. Despite financial challenges due to a net loss and cash reductions, NuCana is strategically advancing its clinical programs into 2025.
Read more →NCNANotice of General Meeting Monday, 7th April 2025 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 1 NOTICE OF GENER
NuCana plc has announced a general meeting scheduled for April 7, 2025, to discuss key resolutions aimed at restructuring the company’s share capital. These resolutions seek to allow the company to issue new American Depositary Shares (ADSs) in order to support its business plans. The board emphasizes that the proposals are critical for maintaining financing options and urges shareholders to vote in favor. Attendance and voting by proxy are encouraged to ensure the resolutions are passed.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2024 2023 2024 2023 (in thousands, except per share data) Resear
NuCana PLC reported its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024. The company experienced a significant operating loss of £5.3 million in Q3 2024, although research and development expenses saw a decline. The total comprehensive loss for the period reached £4.6 million, indicating a worsening financial position year-over-year. The company's cash and cash equivalents decreased notably during this period, raising concerns over its liquidity.
Read more →NCNANuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and wer
NuCana announced initial data from its Phase 1b/2 modular study of NUC-3373, showing promising anti-cancer activity when combined with pembrolizumab in patients with advanced solid tumors. In the first module, the therapy resulted in significant tumor reductions and high disease control rates. However, enrollment in the second module involving docetaxel was paused due to toxicity issues, though some patients experienced prolonged stable disease. The company remains optimistic about the potential benefits for patients who have exhausted other treatment options.
Read more →NCNANuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States Edinburgh, United Kingdom
NuCana plc announced the issuance of a composition-of-matter patent for NUC-7738 by the USPTO, which bolsters its intellectual property protections. The novel anti-cancer agent is undergoing Phase 2 clinical trials in combination with pembrolizumab for patients resistant to PD-1 inhibitors. Recent data presented at ESMO Congress 2024 indicated that NUC-7738 may improve progression-free survival for melanoma patients, significantly surpassing existing treatments. The company's focus is on enhancing cancer therapy outcomes through innovative ProTide technology.
Read more →NCNANuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Combination of NUC-7738 plus Pembrolizumab Resulted in
NuCana presented promising data on NUC-7738 in combination with pembrolizumab at the ESMO Congress 2024. In a cohort of 12 metastatic melanoma patients who had previously been treated with PD-1 inhibitors, 75% achieved disease control, including notable tumor reductions. The combination therapy showcased a favorable safety profile, with some patients exceeding typical progression-free survival times. Data indicates that NUC-7738 may enhance sensitivity to PD-1 inhibitors by targeting tumor microenvironment factors, suggesting potential broader applications beyond melanoma.
Read more →NCNANuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee NuTide:701 and NuTide:303 S
NuCana announced the discontinuation of its Phase 2 randomized colorectal cancer study, NuTide:323, following a pre-planned analysis that suggested the investigational drug NUC-3373 was unlikely to meet its primary goal of superior progression-free survival compared to the control treatment. Despite this setback, ongoing studies, such as NuTide:303 and NuTide:701, continue unaffected, with encouraging data expected to be presented at the upcoming ESMO Annual Conference. The company remains committed to advancing its cancer therapies with insights gained from the NuTide:323 study.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2024 2023 2024 2023 (in thousands, except per share data) Research and deve
NuCana plc reported its unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024. The company experienced an increase in research and development expenses and operating losses compared to the previous year. Additionally, cash and cash equivalents saw a significant reduction, while the accumulated deficit rose further, reflecting ongoing financial challenges. Overall, these figures indicate a difficult financial position for the company as it continues its operations in cancer treatment development.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2024 2023 (in thousands, except per share data) Research and development expenses (6,783 ) (6,805 ) Administ
NuCana PLC released its unaudited condensed consolidated financial statements for the three months ended March 31, 2024. The report indicates a loss for the period amounting to 6,838, a slight improvement from the 7,867 loss recorded in the same period of the previous year. Total assets have decreased from 27,811 to 24,801, and cash and cash equivalents have dropped significantly to 12,868 from 17,225. Administrative expenses were lower this quarter compared to last year, yet the overall financial health appears to be under strain due to increased losses.
Read more →NCNANotice f 2024 Annual General Meeting Tuesday, 18th June 2024 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K. NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTI
NuCana plc announces its 2024 Annual General Meeting scheduled for June 18, 2024, in Edinburgh. The meeting will address various resolutions, including the re-election of directors and the appointment of auditors. Shareholders are encouraged to vote in advance and can appoint the Chair as their proxy. The company seeks approval for share issuance proposals aimed at supporting its business and growth strategy, emphasizing the need for timely execution in a competitive market.
Read more →NCNANuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Edinburgh, United Kingdom
NuCana plc (NASDAQ: NCNA) announced it has regained compliance with Nasdaq's minimum bid price requirement after its American Depositary Shares closed above $1.00 for 10 consecutive business days. Previously, the company was notified of non-compliance, which prompted a compliance period extension from Nasdaq. The company is focused on improving cancer treatment through its ProTide technology, currently evaluating its drug candidates NUC-3373 and NUC-7738 in various clinical studies. This development reaffirms NuCana's position in the biopharmaceutical market as it moves forward with its innovative therapies.
Read more →NCNANuCana Announces Completion of ADS Ratio Change Edinburgh, United Kingdom
NuCana plc announced the effective completion of its ADS Ratio Change, reducing the ratio from one ADS representing one ordinary share to one ADS for twenty-five ordinary shares. This adjustment is designed to improve liquidity and ensure compliance with Nasdaq's minimum bid requirements. Existing ADS holders will automatically see their securities adjusted without affecting their proportional equity. However, the company cannot assure a proportional increase in trading price post-change.
Read more →NCNANuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumor
NuCana plc presented new data at the AACR Annual Meeting regarding NUC-7738, which demonstrates its ability to significantly alter tumor biology by affecting lipid metabolism and ribosome biogenesis in cancer cells. The findings suggest that NUC-7738 can modify the tumor microenvironment, potentially making tumors less aggressive and improving treatment effectiveness, particularly in combination with pembrolizumab. This data could guide the further development of NUC-7738 as a therapeutic option for patients with advanced solid tumors.
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Pipeline Continues to Ad
NuCana plc reported its fourth quarter and year-end 2023 financial results, highlighting encouraging developments for its ProTide therapeutics, particularly NUC-3373 and NUC-7738. The company noted improvements in net loss when compared to 2022, with a cash position expected to support operations into 2025. Full recruitment for a Phase 2 study of NUC-3373 has been achieved, and several data readouts are anticipated in 2024 as the company continues its clinical advancements.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2023 2022 2023 2022 (in thousands, except per share data) Resear
NuCana PLC has released its unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2023. The company reported significant financial losses, with an operating loss of $8.25 million for the quarter and a total comprehensive loss of $19.98 million for the nine-month period. Additionally, the accumulated deficit has risen to over $200 million, reflecting the ongoing financial challenges. Cash reserves have diminished considerably, impacting the company's liquidity position amidst its developmental efforts in biopharmaceuticals.
Read more →NCNANuCana Announces Listing Transfer to Nasdaq Capital Market Edinburgh, United Kingdom
NuCana plc has announced the transfer of its American Depositary Shares listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective November 9, 2023. The company received this approval due to meeting market value requirements, but it must now address the bid price of its ADSs, which needs to exceed $1.00 for at least ten consecutive days. To facilitate this, Nasdaq has granted NuCana an additional 180 days to regain compliance. The company continues to develop its cancer treatment products, NUC-3373 and NUC-7738, as part of its pipeline.
Read more →NCNANuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of
NuCana plc presented data on its drug NUC-7738 at the AACR-NCI-EORTC 2023 conference, indicating its potential effectiveness in patients with metastatic melanoma who have previously been treated with immunotherapy. The ongoing Phase 2 NuTide:701 study shows that NUC-7738, used alone or with pembrolizumab, has led to tumor volume reductions and longer treatment durations. Biopsy data suggests that NUC-7738 may enhance the activity of anti-PD-1 agents, representing a significant advancement in treatment options for refractory patients.
Read more →NCNANuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 NUC-3373 Demonstrates Promising Anti-Tumor Activity and a
NuCana plc presented encouraging data on NUC-3373 for colorectal cancer at the AACR-NCI-EORTC conference. The data highlighted that NUC-3373, used in combination therapies, showed promising anti-tumor activity and a favorable safety profile in second-line patients. Notably, several patients achieved longer progression-free survival compared to their previous treatments. The ongoing clinical studies, including the randomized NuTide:323 trial, are progressing well without any reported new safety concerns.
Read more →NCNANuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 Edinburgh, United Kingdom
NuCana plc (NASDAQ: NCNA) announced its participation in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, scheduled for October 11-15 in Boston. The company will present four studies focusing on its product candidates NUC-3373 and NUC-7738, which are undergoing clinical trials aimed at improving treatment outcomes for colorectal cancer and other solid tumors. The presentations include pivotal data expected to attract attention within the oncology community. NuCana aims to address significant limitations of existing chemotherapy treatments through its innovative ProTide technology.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2023 2022 2023 2022 (in thousands, except per share data) Research and deve
NuCana plc reported its unaudited condensed consolidated financial statements for the three and six months ended June 30, 2023. The company recorded an operating loss of £6,277, higher than the £5,218 loss reported in the same period of the previous year. Additionally, the net loss for the period surged to £5,414, indicating a decline in financial performance. The total comprehensive loss also reflected an increase, highlighting ongoing challenges for the company.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2023 2022 (in thousands, except per share data) Research and development expenses (6,805 ) (9,446 ) Administ
NuCana PLC released its unaudited condensed consolidated statements of operations for the three months ended March 31, highlighting a reduced operating loss compared to the previous year. The company reported a decrease in research and administrative expenses but still faced significant losses with a reported loss for the period of $7,867,000. While finance income improved, total assets declined, reflecting ongoing financial pressures as the company continues its development of new cancer treatments. The results indicate a cautious outlook as the company manages its expenses amid consistently high losses.
Read more →NCNANOTICE OF 2023 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2023 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2023 annual general meeting o
NuCana plc has scheduled its 2023 annual general meeting for June 15, 2023, at Lochside House in Edinburgh. The meeting will involve discussions and voting on various ordinary and special resolutions proposed by the board. Key items on the agenda include the re-election of directors and the re-appointment of Ernst & Young LLP as auditors, with the board encouraging shareholders to vote in favor of all proposed resolutions. Shareholders are advised to vote in advance via proxy for their convenience.
Read more →NCNANuCana Announces Receipt of Nasdaq Notice Edinburgh, United Kingdom
NuCana plc has received a notification from Nasdaq regarding its American Depositary Shares, which have been trading below the required minimum bid price. The company has a grace period of 180 days to comply with the listing requirements, during which its shares will continue to trade. NuCana intends to monitor the stock price closely and evaluate options for regaining compliance. The company remains focused on advancing its clinical pipeline aimed at improving cancer treatment outcomes.
Read more →NCNANuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Gl
NuCana presented promising data at the AACR 2023 Annual Meeting regarding their investigational drug NUC-7738. The findings suggest that NUC-7738 reduces secreted forms of PD-L1 in both melanoma cell lines and patients, indicating potential for synergy with PD-L1 inhibitors. Additionally, NUC-7738 has demonstrated the ability to decrease glutaminase levels in cancer cells, showing potential anti-cancer activity in aggressive tumors. The drug is currently being evaluated in combination with pembrolizumab for patients with advanced solid tumors.
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 Edinburgh, United K
NuCana plc reported its financial results for Q4 and year-end 2022, showing progress in its clinical programs with product candidates NUC-3373 and NUC-7738 advancing to Phase 2 studies. The company noted a net loss of $15.2 million for Q4 and $32 million for the full year, although cash reserves are anticipated to support operations into 2025. Looking ahead, NuCana expects several important data readouts throughout 2023, which could shape the future development and validation of its ProTide therapeutics aimed at improving cancer treatment outcomes.
Read more →NCNATechnical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana s 190 Patent is Not Valid Ruling Has No Impact on NuCana s Anti-Cancer ProTide Patents Munich, Germany
NuCana plc announced that the Technical Board of Appeal of the European Patent Office has ruled that their European Patent 2955190, referred to as the 190 patent, is not valid. This decision reverses earlier conclusions made by the Examination and Opposition divisions of the EPO. However, NuCana clarified that this ruling does not affect its anti-cancer ProTide patents, and it remains focused on advancing its clinical programs. The company is well-capitalized and anticipates forthcoming data announcements for its innovative cancer treatments.
Read more →NCNANuCana Announces Receipt of NASDAQ Notice Edinburgh, United Kingdom
NuCana plc announced receiving a notification from Nasdaq regarding non-compliance with listing rules due to its stock price falling below $1.00 per share. The company has a 180-day grace period to regain compliance, during which its shares will continue to trade. NuCana is actively assessing its options to meet the minimum price requirement, or it may consider transferring its listing if necessary. Despite the notification, the company's ongoing operations and clinical trials remain unaffected.
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2022 2021 2022 2021 (in thousands, except per share data) Resear
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2022 2021 2022 2021 (in thousands, except per share data) Research and development expenses (7,386 ) (8,971 )
Read more →NCNANuCana Presents Positive Data on NUC-3373 at the 34 th EORTC-NCI-AACR Annual Meeting 2022 NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells N
NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022 NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in C
Read more →NCNANuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of S
NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pe
Read more →NCNANuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and
NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and Irinotecan (NUFIRI) in Heavily Pre-Treated Colorectal Cancer Patients
Read more →NCNANuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022 Edinburgh, United Kingdom
NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022 Edinburgh, United Kingdom, September 6, 2022 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 (in thousands, except per share data) Notes Research and development expenses ( 6,40
Read more →NCNAGerman Court Rules that Gilead s Sofosbuvir Infringes NuCana s 190 Patent Edinburgh, United Kingdom
German Court Rules that Gilead s Sofosbuvir Infringes NuCana s 190 Patent Edinburgh, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the Court ) issu
Read more →NCNANuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to S
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Data Indicates Potential Clinical Utility Beyond Solid Tu
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2022 2021 (in thousands, except per share data) Research and development expenses (9,446 ) (8,706 ) Administ
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2022 2021 (in thousands, except per share data) Research and development expenses (9,446 ) (8,706 ) Administrative expenses (2,152 ) (2,104 ) Net foreign
Read more →NCNANOTICE OF 2022 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2022 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2022 annual general meeting o
NOTICE OF 2022 ANNUAL GENERAL MEETING 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2022 ANNUAL NOTICE is hereby given that the 2022 annual general meeting of NuCana plc (the Company ) will be held on 23 June 2022 at 11.00am at Lochside Ho
Read more →NCNANuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Ini
NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal
Read more →NCNANuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022 Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a
NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022 Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-
Read more →NCNANuCana Announces Update for Phase 3 Biliary Tract Cancer Study Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts and Dosing
Read more →NCNANuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in
NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2021 2020 2021 2020 (in thousands, except per share data) Resear
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2021 2020 2021 2020 (in thousands, except per share data) Research and development expenses (8,971 ) (6,117 )
Read more →NCNANuCana Appoints Elliott M. Levy, M.D. to its Board of Directors Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCana Edinburgh, United Kingdom
NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCana Edinburgh, United Kingdom, November 1, 2021 (GLOBE NEWSWIRE) NuCana plc (Nasdaq: NCNA)
Read more →NCNANuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin (NUC-1031) for the Treatment of Biliary Tract Cancer Edinburgh, United Kingdom
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin (NUC-1031) for the Treatment of Biliary Tract Cancer Edinburgh, United Kingdom, September 29, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Adm
Read more →NCNANuCana Announces Four Poster Presentations at the ESMO Congress 2021 NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Phas
NuCana Announces Four Poster Presentations at the ESMO Congress 2021 NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Phase 1 Study Demonstrated Encouraging Efficacy Signals and
Read more →NCNANuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in t
NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022 Data from First Interim Analysis May
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30 For the Six Months Ended June 30, Notes 2021 2020 2021 2020 (in thousands, except per share data) Research and devel
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30 For the Six Months Ended June 30, Notes 2021 2020 2021 2020 (in thousands, except per share data) Research and development expenses (8,523 ) (5,863 ) (17,229 )
Read more →NCNANuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer Seasoned Physician-Executive Further Strengthens Leadership Team Edinburgh, United Kingdom
NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer Seasoned Physician-Executive Further Strengthens Leadership Team Edinburgh, United Kingdom, August 10, 2021 (GLOBE NEWSWIRE) NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improvin
Read more →NCNANUCANA NuCana plc Notice of Annual General Meeting Thursday 24 June 2021 at 11.00am Venue Lochside House, 3 Lochside Way, Edinburgh, EH12 9DT, UK NOTICE OF 2021 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, Lond
NUCANA NuCana plc Notice of Annual General Meeting Thursday 24 June 2021 at 11.00am Venue Lochside House, 3 Lochside Way, Edinburgh, EH12 9DT, UK NOTICE OF 2021 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2021 2020 (in thousands, except per share data) Research and development expenses (8,706 ) (5,938 ) Administ
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2021 2020 (in thousands, except per share data) Research and development expenses (8,706 ) (5,938 ) Administrative expenses (2,104 ) (1,609 ) Net foreign
Read more →NCNANuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced C
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 Edinburgh, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update Presented Encouraging Clinical Data for NUC-3373 and NUC-7738 Continued to Enroll Global Phase III Biliary Tract Cancer Study
NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update Presented Encouraging Clinical Data for NUC-3373 and Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval
Read more →NCNANuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre- Treated Patients with Metastatic Colorectal Cancer Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patien
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Treated Patients with Metastatic Colorectal Cancer Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safet
Read more →NCNANuCana Appoints Andrew Kay as Board Chairman Pharmaceutical Executive Brings a Wealth of Experience to NuCana s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy
NuCana Appoints Andrew Kay as Board Chairman Pharmaceutical Executive Brings a Wealth of Experience to NuCana s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics Edinburgh, United Kingdom, December 21, 202
Read more →NCNAFinal Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist Acelarin plus Cisplatin s High Objective Response Rate and Fa
Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist Acelarin plus Cisplatin s High Objective Response Rate and Favorable Safety NuTide:121 Global Phase III Study Recruit
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2020 2019 2020 2019 (in thousands, except per share data) Resear
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2020 2019 2020 2019 (in thousands, except per share data) Research and development expenses (6,117 ) (4,845 )
Read more →NCNANuCana Expands its Board of Directors with the Appointment of Bali Muralidhar Abingworth Makes Significant Investment in NuCana s Recent $80 million Public Offering Edinburgh, United Kingdom
NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar Abingworth Makes Significant Investment in NuCana s Recent $80 million Public Offering Edinburgh, United Kingdom, October 13, 2020 (GLOBE NEWSWIRE) NuCana plc, a clinical-stage biopharmaceutical compa
Read more →NCNANuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares Edinburgh, United Kingdom
NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares Edinburgh, United Kingdom, September 21, 2020 (GLOBE NEWSWIRE) NuCana plc, a clinical-stage biopharmaceutical co
Read more →NCNANuCana Announces Pricing of a Public Offering of American Depositary Shares Edinburgh, United Kingdom
NuCana Announces Pricing of a Public Offering of American Depositary Shares Edinburgh, United Kingdom, September 17, 2020 (GLOBE NEWSWIRE) NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, anno
Read more →NCNANuCana Announces Proposed Public Offering of American Depositary Shares Edinburgh, United Kingdom
NuCana Announces Proposed Public Offering of American Depositary Shares Edinburgh, United Kingdom, September 16, 2020 (GLOBE NEWSWIRE) NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announce
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30 For the Six Months Ended June 30, Notes 2020 2019 2020 2019 (in thousands, except per share data) Research and devel
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30 For the Six Months Ended June 30, Notes 2020 2019 2020 2019 (in thousands, except per share data) Research and development expenses (5,863 ) (5,356 ) (11,801 )
Read more →NCNANuCana plc Notice of Annual General Meeting Thursday 25 June 2020 at 11.00am Venue Lochside House, 3 Lochside Way, Edinburgh, EH12 9DT, UK NOTICE OF 2020 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, Eng
NuCana plc Notice of Annual General Meeting Thursday 25 June 2020 at 11.00am Venue Lochside House, 3 Lochside Way, Edinburgh, EH12 NOTICE OF 2020 ANNUAL GENERAL MEETING NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2020 ANNUAL GENE
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2020 2019 (in thousands, except per share data) Research and development expenses (5,938 ) (4,350 ) Administ
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2020 2019 (in thousands, except per share data) Research and development expenses (5,938 ) (4,350 ) Administrative expenses (1,609 ) (1,346 ) Net foreign
Read more →NCNANuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic Edinburgh, United Kingdom
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic Edinburgh, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple cli
Read more →NCNANuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acela
NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expr
Read more →NCNANuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121 ) Edinburgh, United Kingdom
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121 ) Edinburgh, United Kingdom, May 5, 2020 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in Nu
Read more →NCNANuCana Provides Update on Impact of COVID-19 on Clinical Studies Edinburgh, United Kingdom
NuCana Provides Update on Impact of COVID-19 on Clinical Studies Edinburgh, United Kingdom, April 2, 2020 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the s
Read more →NCNANuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-tre
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines
Read more →NCNANuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer EDINBURGH, United Kingdom
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer EDINBURGH, United Kingdom, March 4, 2020 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced that the European Med
Read more →NCNANuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Global NuTide:121 Study Is Enrolling up to 828 Pati
NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabin
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2019 2018 2019 2018 (in thousands, except per share data) Resear
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2019 2018 2019 2018 (in thousands, except per share data) Research and development expenses (4,845 ) (3,333 )
Read more →NCNANuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Id
NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of October 29, 2019 (GLOB
Read more →NCNANuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acel
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primar
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2019 2018 2019 2018 (in thousands, except per share data) Research and deve
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2019 2018 2019 2018 (in thousands, except per share data) Research and development expenses (5,356 ) (5,158 ) (9,706 )
Read more →NCNAEnrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis Imbalances in Prognostic Factors May Have Impacted Analys
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis Imbalances in Prognostic Factors May Have Impacted Analysis Longer-term Follow-up by Study Sponsor is Ongoing to D
Read more →NCNANuCana Announces First Patients Dosed in Phase I Study of NUC-7738 NUC-7738 is NuCana s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors Edinburgh, United Kingdom
NuCana Announces First Patients Dosed in Phase I Study of NUC-7738 NUC-7738 is NuCana s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors Edinburgh, United Kingdom, July 17, 2019 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA), a clini
Read more →NCNANuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin for the Treatment of Biliary Tract Cancer NuCana Remains on Track to Open Global Phase III Study in 2019 Edinburgh, United K
NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin for the Treatment of Biliary Tract Cancer NuCana Remains on Track to Open Global Phase III Study in 2019 Edinburgh, United Kingdom, June 12, 2019 (GLOBE NEWSWIRE) NuCana plc (NASDAQ
Read more →NCNANuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2019 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2019 annual general meeting of NuCana plc (the Company ) will be he
77-78 Cannon Street, London, England, EC4N 6AF Company number: 03308778 NOTICE OF 2019 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2019 annual general meeting of NuCana plc (the Company ) will be held on 27 June 2019 at 11.00am at the Gathering Room 2, Norton House
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2019 2018 (in thousands, except per share data) Research and development expenses (4,350 ) (3,705 ) Administ
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2019 2018 (in thousands, except per share data) Research and development expenses (4,350 ) (3,705 ) Administrative expenses (1,346 ) (1,240 ) Net foreign
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company
NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 Edinburgh, United Kingdom, March 7, 2019 (GLOB
Read more →NCNANuCana plc Announces Withdrawal of Public Offering of ADSs Edinburgh, United Kingdom
NuCana plc Announces Withdrawal of Public Offering of ADSs Edinburgh, United Kingdom, January 25, 2019 (GLOBE NEWSWIRE) NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the Company ) focused on significantly improving treatment outcomes for patients with c
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2018 2017 2018 2017 (in thousands, except per share data) Resear
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2018 2017 2018 2017 (in thousands, except per share data) Research and development expenses (3,333 ) (10,177 )
Read more →NCNANuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer NuTide:302 Study Will Evaluate NUC-3373 in Combination with Other Agents Typically Administered with 5-FU Edinburgh, Un
NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer NuTide:302 Study Will Evaluate NUC-3373 in Combination with Other Agents Typically Administered with 5-FU Edinburgh, United Kingdom, November 1, 2018 (GLOBE NEWSWIRE) NuCana p
Read more →NCNANuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin ) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018 50% Objective Response Rate on Intent-to-Treat Basis Observed Phase III Stud
NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin ) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018 50% Objective Response Rate on Intent-to-Treat Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer Planned Edinb
Read more →NCNANuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress Edinburgh, United Kingdom
NuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress Edinburgh, United Kingdom, October 9, 2018 (GLOBE NEWSWIRE) NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly imp
Read more →NCNANUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2018 2017 2018 2017 (in thousands, except per share data) Research and deve
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2018 2017 2018 2017 (in thousands, except per share data) Research and development expenses (5,158 ) (2,077 ) (8,863 )
Read more →NCNANuCana Reports Second Quarter 2018 Financial Results and Provides Business Update Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October Edinburgh, United Kingdom
NuCana Reports Second Quarter 2018 Financial Results and Provides Business Update Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October Edinburgh, United Kingdom, August 28, 2018 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced financial results for the s
Read more →NCNANuCana PLC Company number: 03308778 77-78 Cannon Street, London, England, EC4N 6AF NOTICE OF 2018 ANNUAL GENERAL MEETING NOTICE is hereby given that the 2018 annual general meeting of NuCana plc (the Company ) will be he
Company number: 03308778 77-78 Cannon Street, London, England, EC4N 6AF NOTICE OF 2018 ANNUAL GENERAL MEETING given that the 2018 annual general meeting of NuCana plc (the Company ) will be held on 27 June 2018 at 11.00 am at The Patio Room, Norton House Hotel, Ingliston, Edin
Read more →NCNANuCana Reports First Quarter 2018 Financial Results Edinburgh, United Kingdom
NuCana Reports First Quarter 2018 Financial Results Edinburgh, United Kingdom, May 23, 2018 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced financial resu
Read more →NCNANuCana Announces Appointment of Cyrille Leperlier to its Board of Directors Edinburgh, United Kingdom
NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors Edinburgh, United Kingdom, May 21, 2018 (GLOBE NEWSWIRE) NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients,
Read more →NCNANuCana plc Announces Appointment of Adam George to its Board of Directors Edinburgh, United Kingdom
NuCana plc Announces Appointment of Adam George to its Board of Directors Edinburgh, United Kingdom, April 9, 2018 (GLOBE NEWSWIRE) NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by
Read more →NCNANuCana Reports Financial Results for the Year Ended
NuCana Reports Financial Results for the Year Ended December 31, 2017 Edinburgh, United Kingdom, March 21, 2018 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) announced financial results for the year ended December 31, 2017 and provided an update on its extensive clinical program
Read more →NCNANuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin ) as Front-Line Treatment of Advanced Biliary Tract Cancer NuCana Planning to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary
NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin ) as Front-Line Treatment of Advanced Biliary Tract Cancer to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary Tract Cancer Edinburgh, United Kingdom, January 19, 2018 (GLOBE NEWSWIRE)
Read more →Competitive Position
How NCNA ranks across every disease it competes inCompetitive Position is a premium feature
See how NCNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial